Cancer Biotherapy and Radiopharmaceuticals
Publication Venue For
Pazopanib combined with radiation: in vivo model of interaction.
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Progress in cancer therapy.
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.
Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs.
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513))
Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Clinically useful marrow dosimetry for targeted radionuclide therapy.
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.
A novel monoclonal antibody design for radioimmunotherapy.
Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity.
Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
Gene therapy for the treatment of cancer.
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.
Update: Gene therapy for the treatment of cancer
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
Dosimetry for radioimmunotherapy: a rapidly evolving field.
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.
Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Synthesis and biodistribution of peptide based 99mTc/186Re-MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts.
International Standard Serial Number (issn)
Electronic International Standard Serial Number (eissn)